| Literature DB >> 31362429 |
Sabrina Esposito1, Alessandro Bianco2, Rosita Russo2, Antimo Di Maro2, Carla Isernia2, Paolo Vincenzo Pedone2.
Abstract
A large range of chronic and degenerative diseases can be prevented through the use of food products and food bioactives. This study reports the health benefits and biological activities of the Urtica dioica (U. dioica) edible plant, with particular focus on its cancer chemopreventive potential. Numerous studies have attempted to investigate the most efficient anti-cancer therapy with few side effects and high toxicity on cancer cells to overcome the chemoresistance of cancer cells and the adverse effects of current therapies. In this regard, natural products from edible plants have been assessed as sources of anti-cancer agents. In this article, we review current knowledge from studies that have examined the cytotoxic, anti-tumor and anti-metastatic effects of U. dioica plant on several human cancers. Special attention has been dedicated to the treatment of breast cancer, the most prevalent cancer among women and one of the main causes of death worldwide. The anti-proliferative and apoptotic effects of U. dioica have been demonstrated on different human cancers, investigating the properties of U. dioica at cellular and molecular levels. The potent cytotoxicity and anti-cancer activity of the U. dioica extracts are due to its bioactive natural products content, including polyphenols which reportedly possess anti-oxidant, anti-mutagenic and anti-proliferative properties. The efficacy of this edible plant to prevent or mitigate human cancers has been demonstrated in laboratory conditions as well as in experimental animal models, paving the way to the development of nutraceuticals for new anti-cancer therapies.Entities:
Keywords: Urtica dioica; breast cancer; cancer therapy; food bioactives; natural products bioactivity; nutraceuticals
Year: 2019 PMID: 31362429 PMCID: PMC6695697 DOI: 10.3390/molecules24152753
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Phenolic compounds from U. dioica roots.
Figure 2Phenols and polyphenols mostly detected in U. dioica leaves. (a) kaempferol-3-O-glucoside; (b) quercetin-3-O-glucoside; (c) rutin; (d) isorhamnetin-3-O-rutinoside.
Anti-cancer activities of U. dioica: cervical, epidermoid, colon, gastric and lung cancer.
| Cancer Cell Lines | IC50 | Effects | References | |
|---|---|---|---|---|
| HeLa human cervical cancer | 5 μg/mL (24 h treatment) | ↓ Proliferation ↓ EGF binding | Wagner 1994 [ | |
| HT29 human colon cancer | 24.7 μg/mL (72 h treatment) | ↓ Proliferation ↑ Apoptosis | Ghasemi 2016 [ | |
| HCT-116 human colon cancer | 23.61 μg/mL (48 h treatment) | ↓ Proliferation ↑ Apoptosis G2/M arrest | Mohammadi 2016 [ | |
| NSCLC H1299 human non-small cell lung cancer | 52.3 μg/mL (72 h treatment) | ↓ Proliferation ↑ Apoptosis extrinsic pathway ↑ caspase 3 ↑ caspase 8 ↑ cPARP ↑ tBid ↑ GADD153 ↑ DR5 G2/M arrest | D’Abrosca 2019 [ |
* The plant extracts and parts used with specified collection sites and the biologically active molecules identified.
Anti-cancer effects of U. dioica: prostate cancer, in-vitro and in-vivo studies.
| Cancer Cell Lines/Tissues/Animal Models | IC50 | Effects | References | |
|---|---|---|---|---|
| Balb/c mouse model of benign prostatic hyperplasia (28 days, 5 mg oral treatment) | ↓ hyperplasia 51.4 % growth inhibition | Lichius 1997 [ | ||
| LNCaP human prostate cancer | ↓ Proliferation 30% (5 day treatment with 1 μg/mL) | Konrad 2000 [ | ||
| prostate tissue from prostate cancer patients | 50 μg/mL (30 min treatment) | ↓ ADA | Durak 2004 [ | |
| rat model of benign prostatic hyperplasia (28 days, 50 mg/Kg oral treatment) | 0.19 mg/mL (28 day treatment) | ↓ hyperplasia ↓ 5α-reductase | Nahata 2012 [ | |
| roots ethanolic extract, β-sitosterol and scopoletin | 0.12 mg/mL (28 day treatment) | |||
| PC3 human prostate cancer | 15.54 μg/mL (48 h treatment) | ↓ Proliferation ↑ Apoptosis intrinsic pathway ↑ caspase 3 ↑ caspase 9 ↓ Bcl-2 G2/M arrest | Mohammadi 2016 [ |
* The plant extracts and parts used with specified collection sites and the biologically active molecules identified. ADA: adenosine deaminase.
Figure 3Molecular structures of selected bioactive phytochemicals isolated from U. dioica.
Biological activities of specific molecules isolated from U. dioica.
| Molecules | Biological Activities | Cells | References |
|---|---|---|---|
| 13-S-hydroxy-9Z, 11E, 15Z-octadecantrienoic acid (oxylipin) | Anti-proliferation ro-apoptotis Stop cell cycle Anti-inflammation | lung cancer chondrocytes | [ |
| Anti-proliferation Anti-EGF binding | cervical cancer epidermoid carcinoma | [ | |
| β-sitosterol | Anti-proliferation Inhibition 5α-reductase | prostate | [ |
| scopoletin | Anti-proliferation Inhibition 5α-reductase Anti-inflammation Pro-apoptotis | prostate prostate cancer | [ |
Anti-cancer effects of U. dioica: breast cancer, in-vitro and in-vivo studies.
| Cancer Cell Lines/ Animal Models | IC50 | Effects | References | |
|---|---|---|---|---|
| MCF-7 human breast cancer | ↓ Proliferation 7% (72 h treatment with 50 μg/mL) | Abu-Dahab 2007 [ | ||
| MCF-7 human breast cancer | 2 mg/mL (72 h treatment) | ↓ Proliferation ↑ Apoptosis intrinsic pathway ↑ caspase 3 ↑ caspase 9 ↑ Bax ↑ Bcl-2 ↑ calpain 1 ↑ calpastatin | Fattahi 2013 [ | |
| MDA-MB-468 human breast cancer | 15.54 μg/mL (48 h treatment) | ↓ Proliferation ↑ Apoptosis intrinsic pathway ↑ caspase 3 ↑ caspase 9 ↓ Bcl-2 | Mohammadi 2016 [ | |
| MDA-MB-468 human breast cancer | 0.59 μM (24 h co-treatment paclitaxel + extract) | ↓ Proliferation ↑ Apoptosis ↓ Migration ↓ Snail-1 ↓ ZEB1, ZEB2, twist G2/M arrest ↓ Cdc2 | Mohammadi 2016 [ | |
| MCF-7 human breast cancer MDA-MB-231human breast cancer 4T1 mouse breast cancer Balb/c mouse model of breast cancer (28 day, 20 mg/Kg injection treatment) | 31.37 mg/mL (48 h treatment) 38.14 mg/mL (48 h treatment) 35.21 mg/mL (48 h treatment) | ↓ Proliferation ↓ Migration ↓ miR-21 ↓ MMP1, MMP9, MMP13, vimentin, CXCR4 ↑ E-cadherin | Mansoori 2017 [ | |
| Balb/c mouse model of breast cancer (28 day, 20 mg/Kg injection treatment) | ↓ Metastasis ↑ Apoptosis intrinsic pathway ↑ caspase 3 ↑ caspase 9 ↓ Bcl-2 ↓ Ki-67 | Mohammadi 2017 [ | ||
| rat model of breast cancer (5.5 months, 50 g/kg food treatment) | ↓ Metastasis ↓ lipid peroxidation ↑ catalase | Telo 2017 [ | ||
| MCF-7 human breast cancer | 2 mg/mL (72 h treatment) | ↓ Proliferation ↑ Apoptosis ↑ ADA ↑ ODC1 | Fattahi 2018 [ | |
| MDA-MB-231 human breast cancer | 2 mg/mL (72 h treatment) | ↓ Proliferation ↑ Apoptosis = ADA ↑ ODC1 |
* The plant extracts and parts used with specified collection sites. ADA: adenosine deaminase; ODC1: ornithine decarboxylase.
Figure 4Schematic drawing of U. dioica anti-cancer effects. Each U. dioica extract and its effects are identified using different color codes. The dashed arrows denote the results obtained with whole extracts; the solid arrows indicate the specific molecules isolated from the extracts and their effects. A generic picture of apoptosis signalling, indicating where and how molecules or extracts of U. dioica act on the different cellular targets, is included. By different images are specified if these results were observed in-vitro or in-vivo, on specific cancer types.